Chinese biopharma stocks plummet after centralized tendering report

Chinese biopharma stocks tumbled Thursday in the wake of media and analyst reports suggesting that pricing discounts on generic drugs under China's centralized procurement program were greater than expected.

State-owned Shanghai Securities News reported significantly discounted prices for drugs in

Read the full 395 word article

How to gain access

Continue reading with a
two-week free trial.